Skip to content

Clinical Performance and Safety of Suture-TOOL

Clinical Performance and Safety of Suture-TOOL for Abdominal Wound Closure in Men and Women Patients Undergoing Elective Open Abdominal Surgery

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05695157
Enrollment
38
Registered
2023-01-23
Start date
2023-01-10
Completion date
2023-08-30
Last updated
2023-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Closure Technique, Incisional Hernia, Laparotomy, Wound Infection

Brief summary

The goal of this single arm intervention study is to investigate the safety and performance of a suturing device for closure of the midline incision after open abdominal surgery. The study population consists of 38 patients selected for open abdominal procedures for malignant and benign colorectal disease. The main question it aims to answer is: • If the device facilitates a Suture-Length to Wound-Length (SL/WL) ratio of 4:1 Participants laparotomy wound will be closed with the device at the end of the operation and closure related data as closure time and SL/WL ratio will be calculated. The wound will be assessed for infection during the postoperative stay and the chart will be reviewed for wound dehiscence and wound infection.

Interventions

DEVICESuture-TOOL

Suture device for fast and standardized closure of the abdominal fascia

Sponsors

Helsingborgs Hospital
CollaboratorOTHER
Cross Research S.A.
CollaboratorINDUSTRY
Suturion AB
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Single arm prospective interventional study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Informed consent: signed written informed consent before inclusion in the investigation 2. Sex, age: male and female patients, ≥ 18 years old 3. Surgery: elective open abdominal surgery for benign or malignant colorectal disease through midline incision. Anticipated incision length ≥ 12 cm 4. Body Mass Index (BMI): 18 - 40 kg/m2 inclusive 5. Full comprehension: ability to comprehend the full nature and purpose of the investigation, including possible risks and side effects; ability to co-operate with the Investigator and to comply with the requirements of the entire investigation.

Exclusion criteria

1. Abdominal Surgery: previous abdominal surgery involving the midline 2. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the investigation according to the Investigator's opinion; existing midline hernia, cutaneous infection, fistula, psoriasis of abdominal skin; morbidly obese patients 3. Pre-operative findings: any pre-operative findings identified by the surgeon/Investigator that may preclude the conduct of the investigation procedures 4. Allergy: history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers could affect the outcome of the investigation 5. Diseases: known or identified at surgery disseminated cancer disease; collagen diseases and immune deficiency disorders, according to the Investigator's opinion. Significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that according to the Investigator's opinion may interfere with the aim of the investigation 6. Life expectancy: life expectancy less than 1 year 7. Medications: any medication that could interfere with the investigation procedures or investigation outcome, according to the Investigator's opinion. Hormonal contraceptives for women are allowed 8. Pregnancy and lactation: positive pregnancy test at screening (if applicable); pregnant or breastfeeding women 9. Vulnerable subjects: Individuals unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced because of a compromised position, expectation of benefits or fear of retaliatory response (ISO 14155:2020 §3.55) will be excluded

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients with Suture length/Wound length (SL/WL) ratio ≥ 4Measured during laparotomy closure.SL/WL-ratio of patients laparotomy closures will be calculated by measuring (centimeter) and dividing the length of used suture with the length of the laparotomy wound.

Secondary

MeasureTime frameDescription
Stitch countMeasured during laparotomy closureNumber of stitches used for laparotomy closure
Numbers of sutures usedCounted during laparotomy closure
Incision closure timeMeasured during laparotomy closureTime (seconds) from first to last knot during laparotomy closure
Surgeons´ comfort with device during closureAfter laparotomy closureVAS assessment
Surgeons´ satisfaction with final closure resultAfter laparotomy closureVAS assessment

Other

MeasureTime frameDescription
Type of adverse device effectsDuring the whole study period of up to 8 monthsIdentification of adverse device effects
Type of device deficienciesDuring the whole study period of up to 8 monthsIdentification of device deficiences
Reasons for unscheduled post-surgery visits45 days after surgeryChart review
Patients with wound infections45 days after surgeryWound infection postoperatively
Reasons for device replacement during surgeryDuring the whole study period of up to 8 monthsIdentification during study period
Incision not following the midline (exposure of rectus muscle)During the whole study period of up to 8 monthsAssessment of midline incision
Thickness of subcutaneous fatDuring the whole study period of up to 8 monthsMeasurement of subcutaneous fat (millimeter)
Glove puncturesDuring the whole study period of up to 8 monthsStandardized assessment of puncture holes
Re-operation(s) number45 days after surgeryChart review
Type of adverse effectsDuring the whole study period of up to 8 monthsAll adverse effects derived by spontaneous, unsolicited reports of the subjects or users/handlers, by observation and by routine open questioning will be collected and reported.

Countries

Sweden

Contacts

Primary ContactLena Toft, RN
lena.toft@skane.se+46(0)424061570
Backup ContactMarcus Edelhamre, MD Phd
marcus.edelhamre@skane.se+46(0)424061555

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026